Lipocalyx
- Company typePrivate
- Founded2011
- HeadquartersHalle, Germany
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Lipocalyx firmographics
Firmographics- Name
- Lipocalyx
- Website
- https://lipocalyx.de
- Company type
- Private
- Founded year
- 2011
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Lipocalyx industry classification
Industry- Product category
- Life-Science Research Reagents
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD)
- akta.pro secondary industries
- Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods) (HLAAACAC), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)
Keywords
Where Lipocalyx is headquartered
LocationHeadquarters
- HQ city
- Halle
- HQ country
- Germany
- HQ region
- Europe
Markets served
Lipocalyx business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations
Lipocalyx product offering
Product offeringCore offering
Lipocalyx GmbH develops and manufactures lipid-based transfection reagents specifically formulated for the delivery of small interfering RNA (siRNA) into eukaryotic cells. The products are sold to research laboratories conducting RNA interference (RNAi) and gene-silencing studies. The company's offering centers on proprietary delivery vehicles designed to improve transfection efficiency and cell viability in molecular and cell biology workflows.
Differentiator
Problem solved
Functional benefit
Products and services
- siRNA Transfection Reagents
Companies that use Lipocalyx
Customer profileIdeal customer profiles1 record
Lipocalyx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Lipocalyx competitors and assessment
Company assessmentEmerging players
- Sirnaomics: Sirnaomics is a clinical-stage siRNA therapeutics developer with proprietary GalNAc and PNP delivery platforms. Comparable to Lipocalyx in focusing on siRNA delivery science, but operating as a therapeutics developer rather than a reagent supplier.
- Precision NanoSystems (Cytiva): Precision NanoSystems (now part of Cytiva) provides lipid-nanoparticle technology and instrumentation for nucleic-acid delivery, including siRNA and mRNA. Comparable to Lipocalyx in tackling the delivery challenge for nucleic-acid therapeutics, though primarily through instrumentation and CDMO services.
Broad incumbents
- Lonza: Lonza offers the Nucleofector electroporation-based transfection platform and broader cell-and-gene services. It overlaps with Lipocalyx in nucleic-acid delivery, though through a mechanistically distinct platform and at much larger scale.
- Arrowhead Pharmaceuticals: Arrowhead is a clinical-stage siRNA therapeutics company whose internal delivery-platform development (TRiM, GalNAc, LNP) competes with Lipocalyx as both a customer and a competitor in siRNA delivery science, despite operating much further downstream.
- Thermo Fisher Scientific: Thermo Fisher, via its Lipofectamine product line, is the dominant incumbent in lipid-based transfection reagents. While it operates a much broader life-sciences portfolio, Lipofectamine is the gold-standard siRNA transfection reagent and directly competes with Lipocalyx's core offering.
- Alnylam Pharmaceuticals: Alnylam pioneered the siRNA therapeutics space (Onpattro, Givlaari, etc.) and has built substantial internal delivery chemistry (GalNAc, lipid formulations). Comparable to Lipocalyx in addressing siRNA delivery, though at vastly greater scale and integration.
Direct peers
- Mirus Bio: Mirus Bio manufactures a broad portfolio of transfection reagents (TransIT, Ingenio) for siRNA, DNA, and mRNA delivery used in research and bioprocessing. It is a comparable specialty reagent supplier competing for the same academic and industrial researchers that Lipocalyx targets.
- Polyplus (Sartorius): Polyplus develops PEI-based and LNP transfection reagents for nucleic-acid delivery research and bioprocessing. Acquired by Sartorius in 2023, it is the most direct competitor to Lipocalyx in the transfection-reagents space, serving siRNA, DNA, and mRNA delivery customers.
- OZ Biosciences: OZ Biosciences is a specialty developer of transfection reagents (DreamFect, Lullaby) for siRNA, DNA, and mRNA delivery in research and preclinical applications. It is a comparable small-to-mid reagent supplier in the same niche as Lipocalyx.
Others
- Bio-Techne: Bio-Techne (including Tocris and ProteinSimple) supplies research reagents and tools to life-science researchers, adjacent to Lipocalyx's customer base. While not a transfection specialist, it represents the downstream tools-and-reagents channel and potential partnership or distribution counterpart.
Market position
Customer concentration
Lipocalyx social profiles
Digital presenceLipocalyx financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lipocalyx leadership team
Management profileNumber of profiles
Profiles2 records
Lipocalyx funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lipocalyx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lipocalyx
What does Lipocalyx do?
Lipocalyx GmbH develops and manufactures lipid-based transfection reagents specifically formulated for the delivery of small interfering RNA (siRNA) into eukaryotic cells. The products are sold to research laboratories conducting RNA interference (RNAi) and gene-silencing studies. The company's offering centers on proprietary delivery vehicles designed to improve transfection efficiency and cell viability in molecular and cell biology workflows.
When was Lipocalyx founded?
Lipocalyx was founded in 2011. It employs 1 to 10 people.
Where is Lipocalyx based?
Lipocalyx is headquartered in Halle, Germany, in the Europe region.
Who are Lipocalyx's main competitors?
Emerging players on record are Sirnaomics and Precision NanoSystems (Cytiva). Broad incumbents are Lonza, Arrowhead Pharmaceuticals, Thermo Fisher Scientific and Alnylam Pharmaceuticals. Direct peers are Mirus Bio, Polyplus (Sartorius) and OZ Biosciences. Bio-Techne is listed as an others.
Does Lipocalyx have an API?
No public API is recorded for Lipocalyx.
What industry is Lipocalyx in?
Lipocalyx's product category is Life-Science Research Reagents. Its primary akta.pro industry code is HLAAADAD, RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes), with a secondary code of HLAAACAC, Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods). Its NAICS code is 325414 and its SIC code is 2836.